Absence of Adverse Effects of Oseltamivir on Sleep: A Double-Blind, Randomized Study in Healthy Volunteers in Japan

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 4, 2011, Pages 309-314

  Uchimura, Naohisa ^a   Kuwahara, Hiroo ^a   Kumagai, Yuji ^b   Mishima, Kazuo ^c   Inoue, Yuichi ^d   Rayner, Craig R ^e   Toovey, Stephen ^e   Davies, Brian E ^f   Hosaka, Yoshio ^g   Abe, Masaichi ^g   Prinssen, Eric P ^e  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d NEUROPSYCHIATRIC RESEARCH INSTITUTE   (Japan)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f HOFFMANN LA ROCHE INC   (United States)

^g CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EPISTAXIS; ERYTHEMA; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; INSOMNIA; JAPAN; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL STIFFNESS; NECK PAIN; NORMAL HUMAN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN EROSION; SLEEP DISORDER; SLEEP PARAMETERS; SLEEP STAGE; URINE SEDIMENT;

ANTIVIRAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; OSELTAMIVIR; SLEEP STAGES; YOUNG ADULT;

EID: 80052671421     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00726.x     Document Type: Article

References (32)

1. Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010;65(Suppl. 2):ii5-10.
2. ® (oseltamivir) prescribing information. (last accessed on 25 August 2010).
3. Tamiflu Summary of Product Characteristics. 2009 (last accessed on 25 August 2010).
4. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31:1097-114.
5. Goshima N, Nakano T, Nagao M, Ihara T. A clinical study of abnormal behaviors in patients with influenza. Infect Immun Child 2006;18:371-6.
6. Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J 2006;25:572.
7. Fujita T, Mori M, Okumura A, Hosoya M, Suzuki H, Morishima T et al. Epidemiologic survey of influenza-associated complications II. A statistical analysis of symptoms and signs, and medication. J Jpn Pediatr Soc 2007;111:2.
8. Hirota Y. Survey Research on the Emergence of Influenza-Associated Symptoms. 2007/2008 Research Subteam Report. MHLW Scientific Research Fund, Tokyo, Japan, 2009.
9. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med Gen Med 2007;9:23.
10. Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21years diagnosed with influenza. Int J Adolesc Med Health 2009;21:79-89.
11. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009;63:596-605.
12. Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 2009;53:4753-61.
13. Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother 2008;52:3687-93.
14. Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu®) and active metabolite. Eur J Pharmacol 2010;628:6-10.
15. Mahowald MW. Parasomnias. Med Clin North Am 2004;88:669-78.
16. Sateia MJ. Update on sleep and psychiatric disorders. Chest 2009;135:1370-9.
17. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Satges in Human Subjects. University of California Brain Information Service, Los Angeles, CA, 1968.
18. Atlas Task Force of the American Sleep Disorders Association. EEG arousals: scoring rules and examples. Sleep 1992;15:174-84.
19. Bornemann MA, Mahowald MW, Schenck CH. Parasomnias: clinical features and forensic implications. Chest 2006;130:605-10.
20. Schenck CH, Lee SA, Bornemann MA, Mahowald MW. Potentially lethal behaviors associated with rapid eye movement sleep behavior disorder: review of the literature and forensic implications. J Forensic Sci 2009;54:1475-84.
21. Cartwright R. Sleepwalking violence: a sleep disorder, a legal dilemma, and a psychological challenge. Am J Psychiatry 2004;161:1149-58.
22. Ding M, Toth LA. mRNA expression in mouse hypothalamus and basal forebrain during influenza infection: a novel model for sleep regulation. Physiol Genomics 2006;24:225-34.
23. Majde JA, Kapas L, Bohnet SG, De A, Krueger JM. Attenuation of the influenza virus sickness behavior in mice deficient in Toll-like receptor 3. Brain Behav Immun 2010;24:306-15.
24. Arnulf I, Zeitzer JM, File J, Farber N, Mignot E. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain Dev 2005;128:2763-76.
25. Fukumoto Y, Okumura A, Hayakawa F, Suzuki M, Kato T, Watanabe K et al. Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. Brain Dev 2007;29:425-30.
26. Okumura A, Nakano T, Fukumoto Y, Higuchi K, Kamiya H, Watanabe K et al. Delirious behavior in children with influenza: its clinical features and EEG findings. Brain Dev 2005;27:271-4.
27. Huang YC, Lin TY, Wu SL, Tsao KC. Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. Pediatr Infect Dis J 2003;22:366-8.
28. Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 2007;334:1232-3.
29. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003;26:787-801.
30. Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007;47:689-96.
31. Fuke C, Ihama Y, Miyazaki T. Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu((R)). Leg Med (Tokyo) 2008;10:83-7.
32. Straumanis JP, Tapia MD, King JC. Influenza B infection associated with encephalitis: treatment with oseltamivir. Pediatr Infect Dis J 2002;21:173-5.